Last reviewed · How we verify
nicotine patch + nicotine lozenge
nicotine patch + nicotine lozenge is a Nicotinic acetylcholine receptor agonist Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved for Smoking cessation in adults.
Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine patches and nicotine lozenges are interventions used to treat conditions such as nicotine dependence, smoking cessation, and opioid use disorder, as indicated by ClinicalTrials.gov. The mechanism of action of nicotine, the active ingredient in these interventions, is a small molecule, as classified by ChEMBL.
At a glance
| Generic name | nicotine patch + nicotine lozenge |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Nicotinic acetylcholine receptor agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicotine is a natural alkaloid that acts as an agonist at nicotinic acetylcholine receptors, particularly in the central nervous system. By delivering nicotine through non-combustible routes (patch and lozenge), this combination therapy provides steady systemic exposure while allowing flexible dosing to manage acute cravings, thereby reducing the reinforcing effects of cigarette smoking and easing the transition to abstinence.
Approved indications
- Smoking cessation in adults
Common side effects
- Skin irritation at patch application site
- Mouth irritation or hiccups (lozenge)
- Nausea
- Dizziness
- Insomnia
- Headache
Key clinical trials
- Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers (NA)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Cytisine vs Nicotine Replacement Therapy (NA)
- ACT Lung Health Intervention: Phase Two (NA)
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nicotine patch + nicotine lozenge CI brief — competitive landscape report
- nicotine patch + nicotine lozenge updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI
Frequently asked questions about nicotine patch + nicotine lozenge
What is nicotine patch + nicotine lozenge?
How does nicotine patch + nicotine lozenge work?
What is nicotine patch + nicotine lozenge used for?
Who makes nicotine patch + nicotine lozenge?
What drug class is nicotine patch + nicotine lozenge in?
What development phase is nicotine patch + nicotine lozenge in?
What are the side effects of nicotine patch + nicotine lozenge?
What does nicotine patch + nicotine lozenge target?
Related
- Drug class: All Nicotinic acetylcholine receptor agonist drugs
- Target: All drugs targeting Nicotinic acetylcholine receptors
- Manufacturer: University of Wisconsin, Madison — full pipeline
- Therapeutic area: All drugs in Addiction Medicine / Smoking Cessation
- Indication: Drugs for Smoking cessation in adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing